Skip to main content

Advertisement

SpringerLink
Log in

Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Bevacizumab (BVZ), a monoclonal antibody directed against vascular endothelial growth factor (VEGF), has been suspected to increase the incidence of ischemic stroke (IS) and intracranial hemorrhage (ICH) in GBM patients. Intracranial vascular events, such as IS and ICH, were retrospectively analyzed in 364 MRI scans of 82 patients with recurrent GBM (1st/2nd/3rd relapse). Out of these 82 patients, 40 were treated with BVZ (178 scans) in addition to basic treatment, whereas 42 patients matching for age and gender received basic treatment (186 scans). Distribution of typical vascular risk factors between both groups was analyzed retrospectively. In seven out of 82 patients (8%) vascular events were detected in MRI. Four vascular events were recorded in the BVZ-group (3 IS and 1 ICH), and 3 vascular events were found in the Control-group (1 IS and 2 ICH; p > 0.05 between both groups). Likewise, vascular risk factors (arterial hypertension, diabetes mellitus, obesity, former vascular event, hyperlipidemia, tobacco consumption and/or hypercholesterolemia) did not differ significantly between both groups. BVZ treatment does not seem to be associated with an increased risk for vascular events in patients with GBM in recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507

    Article  CAS  PubMed  Google Scholar 

  2. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403

    Article  PubMed  Google Scholar 

  3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  CAS  PubMed  Google Scholar 

  4. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-oncology 17(Suppl 4):iv1–iv62

    Article  PubMed  PubMed Central  Google Scholar 

  5. Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25(26):4127–4136

    Article  CAS  PubMed  Google Scholar 

  6. Duda DG, Jain RK, Willett CG (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25(26):4033–4042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21(21):2683–2710

    Article  CAS  PubMed  Google Scholar 

  8. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622

    Article  CAS  PubMed  Google Scholar 

  9. Norden AD, Drappatz J, Wen PY (2009) Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5(11):610–620

    Article  CAS  PubMed  Google Scholar 

  10. Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D et al (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-oncology 13(10):1143–1150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740

    Article  CAS  PubMed  Google Scholar 

  12. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953

    Article  CAS  PubMed  Google Scholar 

  13. Heiland DH, Masalha W, Franco P, Machein MR, Weyerbrock A (2016) Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. J Neurooncol 126(3):567–575

    Article  CAS  PubMed  Google Scholar 

  14. Stupp R, Weller M (2014) Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro-oncology 16(6):765–767

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kreisl TN, Toothaker T, Karimi S, DeAngelis LM (2008) Ischemic stroke in patients with primary brain tumors. Neurology 70(24):2314–2320

    Article  PubMed  Google Scholar 

  16. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232–1239

    Article  PubMed  Google Scholar 

  17. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27(29):4865–4873

    Article  CAS  PubMed  Google Scholar 

  18. Kuenen BC (2003) Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb 33(Suppl 1):13–14

    Article  PubMed  Google Scholar 

  19. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D et al (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61(18):6624–6628

    CAS  PubMed  Google Scholar 

  20. Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neuro-oncology 99(1):49–56

    Article  CAS  Google Scholar 

  21. Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM (2011) Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 105(2):281–289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. de Kock I, Mirhosseini M, Lau F, Thai V, Downing M, Quan H et al (2013) Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. J Palliat Care 29(3):163–169

    PubMed  Google Scholar 

  23. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M et al (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32(6):1318–1322

    Article  CAS  PubMed  Google Scholar 

  24. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin Cancer Res 12(16):4899–4907

    Article  CAS  PubMed  Google Scholar 

  25. Cemil B, Tun K, Polat O, Ozen O, Kaptanoglu E (2009) Glioblastoma multiforme mimicking arteriovenous malformation. Turk Neurosurg 19(4):433–436

    PubMed  Google Scholar 

  26. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722

    Article  CAS  PubMed  Google Scholar 

  28. Carden CP, Larkin JM, Rosenthal MA (2008) What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro-oncology 10(4):624–630

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Int Soc Cell 79(1–2):27–38

    CAS  Google Scholar 

  30. Grisold W, Oberndorfer S, Struhal W (2009) Stroke and cancer: a review. Acta Neurol Scand 119(1):1–16

    Article  CAS  PubMed  Google Scholar 

  31. Whitaker RM (1998) Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 279(16):1265–1272

    Article  Google Scholar 

  32. Dorresteijn LD, Kappelle AC, Boogerd W, Klokman WJ, Balm AJ, Keus RB et al (2002) Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 20(1):282–288

    Article  PubMed  Google Scholar 

  33. Wakai S, Yamakawa K, Manaka S, Takakura K (1982) Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 10(4):437–444

    Article  CAS  PubMed  Google Scholar 

  34. Zimmerman RA, Bilaniuk LT (1980) Computed tomography of acute intratumoral hemorrhage. Radiology 135(2):355–359

    Article  CAS  PubMed  Google Scholar 

  35. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62

    Article  CAS  PubMed  Google Scholar 

  36. Eom KS, Kim DW, Kang S (2015) Emergency microsurgical embolectomy in acute ischemic stroke with diffusion-negative MRI. Neurol Neurochir Pol 49(6):432–435

    PubMed  Google Scholar 

  37. Bernick C, Kuller L, Dulberg C, Longstreth WT Jr, Manolio T, Beauchamp N et al (2001) Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57(7):1222–1229

    Article  CAS  PubMed  Google Scholar 

  38. Lim JS, Kwon HM (2010) Risk of “silent stroke” in patients older than 60 years: risk assessment and clinical perspectives. Clin Interv Aging 5:239–251

    PubMed  PubMed Central  Google Scholar 

  39. Vermeer SE, Longstreth WT Jr, Koudstaal PJ (2007) Silent brain infarcts: a systematic review. Lancet Neurol 6(7):611–619

    Article  PubMed  Google Scholar 

  40. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL et al (2015) Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol 33(25):2735–2744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T et al (2016) Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-oncology 18(9):1313–1318

    Article  PubMed  Google Scholar 

  42. Schaub C, Schafer N, Mack F, Stuplich M, Kebir S, Niessen M et al (2016) The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma. J Cancer Res Clin Oncol 142(8):1825–1829

    Article  CAS  PubMed  Google Scholar 

  43. Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Sangatsuda Y et al (2017) Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. OncoTargets Ther 10:429–437

    Article  Google Scholar 

  44. Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T et al (2016) Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-oncology 18(7):991–1001

    Article  PubMed  PubMed Central  Google Scholar 

  45. Sinnadurai M, McDonald KL (2017) Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma. J Neuro-oncology 1–14

Download references

Author information

Authors and Affiliations

  1. Department of Neuroradiology, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131, Mainz, Germany

    Timo A. Auer, Marc A. Brockmann & Yasemin Tanyildizi

  2. Department of Neurosurgery, University Medical Center, Mainz, Germany

    Mirjam Renovanz & Federico Marini

  3. Institute of Medical Biostatistics, Epidemiology and Informatics [IMBEI], University Medical Center, Mainz, Germany

    Federico Marini

Authors
  1. Timo A. Auer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mirjam Renovanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Federico Marini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc A. Brockmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasemin Tanyildizi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasemin Tanyildizi.

Ethics declarations

Conflict of interest

The author(s) declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Auer, T.A., Renovanz, M., Marini, F. et al. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab. J Neurooncol 133, 571–579 (2017). https://doi.org/10.1007/s11060-017-2467-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2467-z

Keywords

Search

Navigation